Skip to main content
Top
Published in: European Radiology 9/2018

01-09-2018 | Urogenital

Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation

Authors: Moozhan Nikpanah, Lauren Kim, S. Mojdeh Mirmomen, Rolf Symons, Ioannis Papageorgiou, William A. Gahl, Kevin O’Brien, Juvianee I. Estrada-Veras, Ashkan A. Malayeri

Published in: European Radiology | Issue 9/2018

Login to get access

Abstract

Objectives

To use magnetic resonance imaging (MRI) and computed tomography (CT) to define abdominal involvement in Erdheim–Chester disease (ECD), and to investigate the association between these findings and the BRAFV600E mutation.

Methods

This prospective study was performed on 61 ECD patients (46 men). The MRI and CT imaging studies were reviewed independently by two experienced radiologists. The association between BRAFV600E mutation and imaging findings was analysed using Fisher’s exact test, and odds ratios with 95% confidence intervals.

Results

Perinephric infiltration was the most common finding (67%), followed by involvement of proximal ureters (61%). In 56% of cases, infiltration extended to the renal sinuses, and in 38% caused hydronephrosis. Adrenal gland infiltration was present in 48% of patients. Infiltration of renal artery (49%) and aorta (43%) were the most common vascular findings, followed by sheathing of celiac, superior mesenteric artery (SMA) or inferior mesenteric artery (IMA) (23%). The BRAFV600E mutation was positive in 53% of patients with interpretable BRAF sequencing. There was a statistically significant association between this mutation and perinephric infiltration (p = 0.003), renal sinus involvement (p < 0.001), infiltration of proximal ureters (p < 0.001), hydronephrosis (p < 0.001), adrenal gland involvement (p < 0.001), periaortic infiltration (p = 0.03), sheathing or stenosis of renal artery (p < 0.001) and sheathing of other aortic branches (p = 0.04).

Conclusions

Renal and vascular structures are the most commonly affected abdominal organs in ECD patients. Some of these findings have significant positive association with the BRAFV600E mutation.

Key Points

• Abdominal imaging plays a crucial role in management of Erdheim–Chester disease.
• Significant associations exist between BRAF V600E mutation and several abdominal imaging findings.
• Considering several associations, evaluating BRAFV600E mutation status is recommended in ECD patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mazor RD, Manevich-Mazor M, Shoenfeld Y (2013) Erdheim–Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis 8:1CrossRef Mazor RD, Manevich-Mazor M, Shoenfeld Y (2013) Erdheim–Chester disease: a comprehensive review of the literature. Orphanet J Rare Dis 8:1CrossRef
2.
go back to reference Bindra J, Lam A, Lamba R, VanNess M, Boutin RD (2014) Erdheim–Chester disease: an unusual presentation of an uncommon disease. Skeletal Radiol 43:835–840CrossRefPubMed Bindra J, Lam A, Lamba R, VanNess M, Boutin RD (2014) Erdheim–Chester disease: an unusual presentation of an uncommon disease. Skeletal Radiol 43:835–840CrossRefPubMed
3.
go back to reference Haroche J, Amoura Z, Dion E et al (2004) Cardiovascular involvement, an overlooked feature of Erdheim–Chester disease: report of 6 new cases and a literature review. Medicine 83:371–392CrossRefPubMed Haroche J, Amoura Z, Dion E et al (2004) Cardiovascular involvement, an overlooked feature of Erdheim–Chester disease: report of 6 new cases and a literature review. Medicine 83:371–392CrossRefPubMed
4.
go back to reference Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390CrossRefPubMedPubMedCentral Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390CrossRefPubMedPubMedCentral
5.
go back to reference Haroche J, Alba O (2015) Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease. Hematology Am Soc Hematol Educ Program 2015:571–578PubMed Haroche J, Alba O (2015) Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease. Hematology Am Soc Hematol Educ Program 2015:571–578PubMed
6.
go back to reference Diamond EL, Dagna L, Hyman DM et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 124:483–492CrossRefPubMedPubMedCentral Diamond EL, Dagna L, Hyman DM et al (2014) Consensus guidelines for the diagnosis and clinical management of Erdheim–Chester disease. Blood 124:483–492CrossRefPubMedPubMedCentral
7.
go back to reference Tan AC, Yzer S, Atebara N et al (2017) Three cases of Erdheim–Chester disease with intraocular manifestations: imaging and histopathology findings of a rare entity. Am J Ophthal 176:141–147CrossRefPubMed Tan AC, Yzer S, Atebara N et al (2017) Three cases of Erdheim–Chester disease with intraocular manifestations: imaging and histopathology findings of a rare entity. Am J Ophthal 176:141–147CrossRefPubMed
8.
go back to reference Haroche J, Arnaud L, Cohen-Aubart F et al (2013) Erdheim–Chester disease. Rheum Dis Clin North Am 39:299–311CrossRefPubMed Haroche J, Arnaud L, Cohen-Aubart F et al (2013) Erdheim–Chester disease. Rheum Dis Clin North Am 39:299–311CrossRefPubMed
9.
go back to reference Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L (2015) Erdheim–Chester disease. Eur J Inter Med 26:223–229CrossRef Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L (2015) Erdheim–Chester disease. Eur J Inter Med 26:223–229CrossRef
10.
go back to reference Cives M, Simone V, Rizzo FM et al (2015) Erdheim–Chester disease: a systematic review. Crit Rev Oncol Hematol 95(1):–11 Cives M, Simone V, Rizzo FM et al (2015) Erdheim–Chester disease: a systematic review. Crit Rev Oncol Hematol 95(1):–11
11.
12.
go back to reference Dion E, Graef C, Haroche J et al (2004) Imaging of thoracoabdominal involvement in Erdheim–Chester disease. Am J Roentgenol 183:1253-1260 Dion E, Graef C, Haroche J et al (2004) Imaging of thoracoabdominal involvement in Erdheim–Chester disease. Am J Roentgenol 183:1253-1260
13.
go back to reference Drier A, Haroche J, Savatovski J et al (2010) Cerebral, facial, and orbital involvement in Erdheim–Chester disease: CT and MR imaging findings 1. Radiology 255:586–594CrossRefPubMed Drier A, Haroche J, Savatovski J et al (2010) Cerebral, facial, and orbital involvement in Erdheim–Chester disease: CT and MR imaging findings 1. Radiology 255:586–594CrossRefPubMed
14.
go back to reference Estrada-Veras JI, O'Brien KJ, Boyd LC et al (2017) The clinical spectrum of Erdheim–Chester disease: an observational cohort study. Blood Adv 1:357–366CrossRefPubMedPubMedCentral Estrada-Veras JI, O'Brien KJ, Boyd LC et al (2017) The clinical spectrum of Erdheim–Chester disease: an observational cohort study. Blood Adv 1:357–366CrossRefPubMedPubMedCentral
15.
go back to reference Emile JF, Abla O, Fraitag S et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–2681CrossRefPubMedPubMedCentral Emile JF, Abla O, Fraitag S et al (2016) Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 127:2672–2681CrossRefPubMedPubMedCentral
16.
go back to reference Zaveri J, La Q, Yamish G, Neuman J (2014) More than just Langerhans cell histiocytosis: a radiologic review of histiocytic disorders. Radiographics 34:2008–2024CrossRefPubMed Zaveri J, La Q, Yamish G, Neuman J (2014) More than just Langerhans cell histiocytosis: a radiologic review of histiocytic disorders. Radiographics 34:2008–2024CrossRefPubMed
17.
go back to reference Gupta A, Yeganeh A, Rootman D, Goldberg R (2017) Vemurafenib (BRAF inhibitor) therapy for orbital Erdheim–Chester disease. Ophthal Plast Reconstr Surg 33:e138–e139CrossRefPubMed Gupta A, Yeganeh A, Rootman D, Goldberg R (2017) Vemurafenib (BRAF inhibitor) therapy for orbital Erdheim–Chester disease. Ophthal Plast Reconstr Surg 33:e138–e139CrossRefPubMed
18.
go back to reference Cangi MG, Biavasco R, Cavalli G et al (2015) BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim–Chester disease. Ann Rheum Dis 74:1596–1602CrossRefPubMed Cangi MG, Biavasco R, Cavalli G et al (2015) BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim–Chester disease. Ann Rheum Dis 74:1596–1602CrossRefPubMed
19.
go back to reference Emile JF, Diamond EL, Hélias-Rodzewicz Z (2014) Recurrent RAS and PIK3CA mutations in Erdheim–Chester disease. Blood 124:3016-3019 Emile JF, Diamond EL, Hélias-Rodzewicz Z (2014) Recurrent RAS and PIK3CA mutations in Erdheim–Chester disease. Blood 124:3016-3019
20.
go back to reference Haroche J, Charlotte F, Arnaud L et al (2012) High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700-2703 Haroche J, Charlotte F, Arnaud L et al (2012) High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood 120:2700-2703
21.
go back to reference Emile JF, Charlotte F, Amoura Z, Haroche J (2012) BRAF mutations in Erdheim–Chester disease. J Clin Oncol 31:398–398CrossRefPubMed Emile JF, Charlotte F, Amoura Z, Haroche J (2012) BRAF mutations in Erdheim–Chester disease. J Clin Oncol 31:398–398CrossRefPubMed
22.
go back to reference Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMed
23.
go back to reference Haroche J, Cohen-Aubart F, Emile JF et al (2013) Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121:1495–1500CrossRefPubMed Haroche J, Cohen-Aubart F, Emile JF et al (2013) Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121:1495–1500CrossRefPubMed
24.
go back to reference Haroche J, Cohen-Aubart F, Emile JF et al (2014) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim–Chester disease. J Clin Oncol 33:411–418CrossRefPubMed Haroche J, Cohen-Aubart F, Emile JF et al (2014) Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAFV600E-mutated Erdheim–Chester disease. J Clin Oncol 33:411–418CrossRefPubMed
25.
go back to reference Gottlieb R, Chen A (2002) MR findings of Erdheim–Chester disease. J Comput Assist Tomogr 26:257–261CrossRefPubMed Gottlieb R, Chen A (2002) MR findings of Erdheim–Chester disease. J Comput Assist Tomogr 26:257–261CrossRefPubMed
26.
go back to reference Antunes C, Graça B, Donato P (2014) Thoracic, abdominal and musculoskeletal involvement in Erdheim–Chester disease: CT, MR and PET imaging findings. Insights Imaging 5:473–482CrossRefPubMedPubMedCentral Antunes C, Graça B, Donato P (2014) Thoracic, abdominal and musculoskeletal involvement in Erdheim–Chester disease: CT, MR and PET imaging findings. Insights Imaging 5:473–482CrossRefPubMedPubMedCentral
27.
go back to reference Yelfimov DA, Lightner DJ, Tollefson MK (2014) Urologic manifestations of Erdheim–Chester disease. Urology 84:218–221CrossRefPubMed Yelfimov DA, Lightner DJ, Tollefson MK (2014) Urologic manifestations of Erdheim–Chester disease. Urology 84:218–221CrossRefPubMed
28.
go back to reference Arnaud L, Hervier B, Néel A et al (2011) CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim–Chester disease: a multicenter survival analysis of 53 patients. Blood 117:2778–2782CrossRefPubMed Arnaud L, Hervier B, Néel A et al (2011) CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim–Chester disease: a multicenter survival analysis of 53 patients. Blood 117:2778–2782CrossRefPubMed
29.
go back to reference De Filippo M, Ingegnoli A, Carloni A et al (2009) Erdheim–Chester disease: clinical and radiological findings. Radiol Med 114:1319CrossRefPubMed De Filippo M, Ingegnoli A, Carloni A et al (2009) Erdheim–Chester disease: clinical and radiological findings. Radiol Med 114:1319CrossRefPubMed
30.
go back to reference Purysko AS, Westphalen AC, Remer EM, Coppa CP, Leão Filho HM, Herts BR (2016) Imaging manifestations of hematologic diseases with renal and perinephric involvement. RadioGraphics 36:1038–1054CrossRefPubMed Purysko AS, Westphalen AC, Remer EM, Coppa CP, Leão Filho HM, Herts BR (2016) Imaging manifestations of hematologic diseases with renal and perinephric involvement. RadioGraphics 36:1038–1054CrossRefPubMed
31.
go back to reference Horvat NSMR, Coelho CR, Roza LC et al (2015) Spectrum of abdominal imaging findings in histiocytic disorders. Abdom Imaging 40:2738–2746CrossRef Horvat NSMR, Coelho CR, Roza LC et al (2015) Spectrum of abdominal imaging findings in histiocytic disorders. Abdom Imaging 40:2738–2746CrossRef
32.
go back to reference Castle EP, Humphreys MR, Andrews PE (2005) Laparoscopic biopsy and ureterolysis in Erdheim–Chester disease. Mayo Clin Proc 80:546–548CrossRefPubMed Castle EP, Humphreys MR, Andrews PE (2005) Laparoscopic biopsy and ureterolysis in Erdheim–Chester disease. Mayo Clin Proc 80:546–548CrossRefPubMed
33.
go back to reference Haroche J, Amoura Z, Touraine P et al (2007) Bilateral adrenal infiltration in Erdheim–Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab 92:2007–2012CrossRefPubMed Haroche J, Amoura Z, Touraine P et al (2007) Bilateral adrenal infiltration in Erdheim–Chester disease. Report of seven cases and literature review. J Clin Endocrinol Metab 92:2007–2012CrossRefPubMed
35.
go back to reference Surabhi VR, Menias C, Prasad SR, Patel AH, Nagar A, Dalrymple NC (2008) Neoplastic and non-neoplastic proliferative disorders of the perirenal space: cross-sectional imaging findings. Radiographics 28:1005–1017CrossRefPubMed Surabhi VR, Menias C, Prasad SR, Patel AH, Nagar A, Dalrymple NC (2008) Neoplastic and non-neoplastic proliferative disorders of the perirenal space: cross-sectional imaging findings. Radiographics 28:1005–1017CrossRefPubMed
36.
go back to reference Scheer M, Hon M, Fruauff AA, Blumenfeld W, Grossman ZD, Katz DS Perinephric xanthogranulomatosis: CT diagnosis and confirmation by CT-guided percutaneous biopsy. Clin Imaging 24:64–67 Scheer M, Hon M, Fruauff AA, Blumenfeld W, Grossman ZD, Katz DS Perinephric xanthogranulomatosis: CT diagnosis and confirmation by CT-guided percutaneous biopsy. Clin Imaging 24:64–67
37.
go back to reference Haroche J, Arnaud L, Cohen-Aubart F et al (2014) Erdheim–Chester disease. Curr Rheumatol Rep 16:412CrossRefPubMed Haroche J, Arnaud L, Cohen-Aubart F et al (2014) Erdheim–Chester disease. Curr Rheumatol Rep 16:412CrossRefPubMed
Metadata
Title
Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAFV600E mutation
Authors
Moozhan Nikpanah
Lauren Kim
S. Mojdeh Mirmomen
Rolf Symons
Ioannis Papageorgiou
William A. Gahl
Kevin O’Brien
Juvianee I. Estrada-Veras
Ashkan A. Malayeri
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 9/2018
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-018-5326-1

Other articles of this Issue 9/2018

European Radiology 9/2018 Go to the issue